{
  "docId": "019de513-bbaf-7632-8c51-2e65d00dc762",
  "docSlug": "d61504792622527e2ff1c803565a1f5e",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 42 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 42,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 40,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de513-bbaf-7632-8c51-2e65d00dc762/9",
  "deckHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762",
  "deckJsonHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762.json",
  "deckAnchorHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.09,
        "x": 0.04,
        "y": 0.94
      },
      "kind": "image",
      "text": "BAUSCH+ LOMB",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6972bd70-01d6-4f6e-a633-5944aece1912",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.38,
        "w": 0.24,
        "x": 0.72,
        "y": 0.36
      },
      "kind": "list",
      "text": "+6% organic revenue growth1,2 Investment YTD in R&D +$14M, ~8% of revenue Continue to maintain a disciplined approach to cost management and leverage our infrastructure",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f623a6fb-4be1-4cc5-b106-6cb047d3c402",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.54,
        "x": 0.148,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. Products with sales outside the United States impacted by F/X changes. 2. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios. 3. Includes transactional FX and NCI. 4. On a proforma basis after giving effect to the IPO.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e770aa27-b0c3-4dbe-8ce5-ec9dae6553f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.73,
        "w": 0.67,
        "x": 0.029,
        "y": 0.148
      },
      "kind": "table",
      "text": "Bausch + Lomb 2Q22 2Q21 Reported Change Constant Currency² Organic Change2 Vision Care Revenue $589M $556M 6% 11% 11% Surgical Revenue $184M $185M (1%) 5% 7% Ophthalmic Pharmaceuticals Revenue $168M $193M (13%) (10%) (10%) Total Revenue $941M $934M 1% 6% 6% Adj. Gross Profit2 $562M $567M (1%) 3% Adj. Gross Margin² 59.7% 60.7% (100 bps) R&D $75M $71M (6%) (8%) R&D percent of Revenues 8.0% 7.6% Adj. SG&A2 $362M $352M (3%) (7%) Adj. SG&A percent of Revenues3 38.5% 37.7% Adj. EBITA2 $125M $144M (13%) (8%) Depreciation $34M $34M 0% 6% Stock Based Compensation $11M $15M (27%) (27%) Adj. EBITDA 2,3 $182M $200M (9%) (7%) Adj. EBITDA Margin² 19.3% 21.4% Adj. Net Income2 $103M $116M (11%) (8%) Adj EPS3,4 $0.29 $0.33",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6c32aea-9ddf-44bf-a3ba-2391f8e6535b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.64,
        "x": 0.048,
        "y": 0.075
      },
      "kind": "title",
      "text": "Total Bausch + Lomb P&L¹ (Non-GAAP)²",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c46841b-36e4-44b9-af83-20595f5a810b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "204eed15-4f33-459f-91fc-d89cd6c5a40f",
      "evidence": "table/data: Bausch + Lomb 2Q22 2Q21 Reported Change Constant Currency² Organic Change2 Vision Care Revenue $589M $556M 6% 11% 11% Surgical Revenue $184M $185M (1%) 5% 7% Ophthalmic Pharmaceuticals Revenue $168M $193M (13",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d0820f93-74dc-4006-a0cc-2e2499a07167",
      "evidence": "The loop opens on slide 6 and closes on slide 15, showcasing the company's opportunities",
      "position": 0,
      "objective": "Highlighting the benefits of a standalone Bausch + Lomb",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}